ライフサイエンスコーパス: perflubron

1 acified nearly completely after each dose of perflubron.

2 airway and lung were filled with radiopaque perflubron.

3 before and after the lungs were filled with perflubron.

4 e oxygenation index after a 15 mL/kg dose of perflubron.

5 incremental dosing of three 5-mL/kg doses of perflubron.

6 ow rate during total liquid ventilation with perflubron.

7 position was affected only after 15 mL/kg of perflubron.

8 the peroxyl radical scavenging properties of perflubron.

9 es were significantly (p < .05) inhibited by perflubron.

10 ted alveolar macrophages were not altered by perflubron.

11 lated alveolar macrophages were treated with perflubron.

12 Cell viability was not affected by perflubron.

13 ntilation or partial liquid ventilation with Perflubron (18 mL/kg by bolus fill).

14 her partial liquid ventilation (n = 16) with perflubron (18 mL/kg via endotracheal tube) or conventio

15 artial liquid ventilation (PLV, n = 15) with perflubron (18 mL/kg via endotracheal tube), conventiona

16 Animals in the PLV group were filled with perflubron (22 ml/kg) until a meniscus at the teeth was

17 Strikingly, treatment with perflubron abrogated nuclear factor-kappa B activation i

18 s were obtained immediately before and after perflubron administration and were scored (0-5) by a rad

19 tion significantly (p < .001) improved after perflubron administration in all partial liquid ventilat

20 The combination of HFOV and perflubron administration is a novel strategy in the tre

21 The combination of HFOV and perflubron administration was well tolerated hemodynamic

22 measured before and after lung injury, after perflubron administration, and then every 4 hrs for 20 h

23 n interval of 6.25 days between scanning and perflubron administration; was patchy in four patients (

24 ctant alone (n = 8); b) priming with the PFC perflubron alone (n = 8); c) priming with perflubron fol

25 66%+/-1% (p < .05; n = 5) after exposure to perflubron and by 63%+/-9% and 68%+/-6% after exposure t

26 Perflubron and FC-77 appear to decrease bacterial adhesi

27 ive animals with the instillation of 30 mUkg perflubron and five animals continued receiving high-fre

28 Five control animals were not dosed with perflubron and remained on HFOV for the 1-hr period of d

29 groups at baseline, after injury, and after perflubron and sham doses.

30 d HFOV mode of ventilation after 10 mL/kg of perflubron, and rotating position was affected only afte

31 onclude that partial liquid ventilation with Perflubron appears to have no negative impact on phospho

32 he lungs of treated animals were filled with perflubron (approximately 18 mL/kg), and the control rab

33 on (CMV), five dogs undergoing low-dose PLV (perflubron at 10 ml/kg), and four dogs undergoing high d

34 kg), and four dogs undergoing high dose PLV (perflubron at 30 ml/kg).

35 quential intratracheal dosing of 10 mL/kg of perflubron at 30-min intervals to the following cumulati

36 ve escalating doses (3, 15, and 30 mL/kg) of perflubron at 60-min intervals.

37 HFO-PLV was initiated by instillation of perflubron at a rate of 0.5 mL.kg-1.min-1 to achieve tot

38 The efficacy of an oxygenated perflubron-based fluorocarbon emulsion (PFE) was tested

39 ng the animal for 30 mins, and then removing perflubron by suctioning.

40 We conclude that HFOV and PLV with perflubron cause similar improvements in gas exchange an

41 Furthermore, PLV with perflubron decreased the number of viable bacteria per g

42 Administration of perflubron did not produce acute alterations of gas exch

43 Perflubron did not serve as a sink for peroxyl radicals

44 frequency oscillatory ventilation [HFOV]) on perflubron distribution and oxygenation improvement.

45 itioning produced significantly more uniform perflubron distribution during both CMV and HFOV.

46 Perflubron distribution, barotrauma, and inability to di

47 en oxygenation improvements and nondependent perflubron distribution.

48 sses were determined using a single 10 mL/kg perflubron dose (n = 5); hourly radiographs were obtaine

49 r prolonged PLV (n = 10), a 10-mL/kg initial perflubron dose was followed every 4 hrs with 5-mL/kg su

50 dress the histopathologic effects of varying perflubron doses during HFOV in a long-term study of the

51 quid ventilation was initiated by instilling perflubron during conventional mechanical ventilation to

52 ored for percentage of lung opacification by perflubron during partial liquid ventilation (PLV) and e

53 n of a perfluorocarbon (PFC) liquid, such as perflubron, during partial liquid ventilation improves l

54 bacterial viability between the control and perflubron-exposed bacteria (n = 5).

55 er 24 hrs, radiographs documented continuous perflubron exposure (postffill = 4.53+/-0.64, prefill =

56 Gas ventilation of the perflubron-filled lung was then performed (PLV).

57 the computed tomographic (CT) appearance of perflubron-filled lungs during partial liquid ventilatio

58 FC perflubron alone (n = 8); c) priming with perflubron followed by surfactant (n = 8); and d) no tre

59 filled to functional residual capacity with perflubron, followed by administration of an additional

60 ith lipopolysaccharide and then treated with perflubron for 23 hrs.

61 roth suspensions of Pasteurella multocida to perflubron for various times.

62 Evaporation of perflubron from the lungs of neonates is relatively rapi

63 Perflubron gradually cleared until it filled less than o

64 By 6 hrs, the majority of perflubron had evaporated (score = 1.75+/-0.53).

65 ovide optimal intrapulmonary distribution of perflubron has not been fully accessed.

66 quid ventilation with the perfluorochemical, perflubron, has been shown to improve lung mechanics and

67 efficacy of partial liquid ventilation with perflubron in 13 premature infants with severe respirato

68 Intratracheal perflubron in a total dose of 30.1 +/- 7.1 ml/kg was adm

69 acy of partial liquid ventilation (PLV) with perflubron in adult patients with acute lung injury and

70 the control rabbits were ventilated without perflubron in an identical fashion.

71 The distribution of perflubron in the lungs is typically gravity dependent.

72 of stimulated human alveolar macrophages to perflubron in vitro decreases cytokine production.

73 and combined effects of iNO, HFOV, and PLV (perflubron) in 31 extremely premature lambs (115 d, 0.78

74 In five patients, perflubron increased the visibility of small pneumothora

75 an additional volume of 30, 45, or 60 mL of perflubron (initial volume = functional residual capacit

76 graphs) were obtained before and after daily perflubron instillation in 13 adults undergoing PLV who

77 ge (n=9) by instilling 1.6 L of unoxygenated perflubron into the trachea and resuming gas ventilation

78 monstrate that treatment of BALB/c mice with perflubron intranasally 6 hours after RSV infection sign

79 Perflubron is more uniformly dispersed when dosed in a r

80 rtial liquid ventilation was instituted with perflubron (LiquiVent, 30 mL/kg) after 30 mins in the No

81 Perflubron may be safely administered into the lungs of

82 This observation suggests that perflubron may have anti-inflammatory activity.

83 ypass with full functional residual capacity perflubron (n = 7), cardiopulmonary bypass with half fun

84 ypass with half functional residual capacity perflubron (n = 7), or cardiopulmonary bypass alone (n =

85 perfluorcarbon-associated gas exchange with perflubron (n=10) or volume controlled continuous positi

86 entilation (GV) and PLV with 10 and 30 ml/kg perflubron on pericardial pressure (Pperi), Pcw, Pla, th

87 nt dosages of the perfluorocarbon LiquiVent (perflubron) on pulmonary vascular permeability and edema

88 Immediately after instillation of perflubron, opacification of more than two-thirds of the

89 by binding of lipid peroxidation products to perflubron or by the peroxyl radical scavenging properti

90 Partial liquid ventilation (PLV) with perflubron (PFB) has been proposed as an adjunct to the

91 t at 5 cm H2O after the lung was filled with perflubron (PFB).

92 /- 0.6 mm Hg, CO = 3.2 +/- 0.1 L/m; 10 ml/kg perflubron: Pperi = -1.3 +/- 0.6 mm Hg, CO = 3.4 +/- 0.2

93 /- 0.6 mm Hg, CO = 3.4 +/- 0.2 L/m; 30 ml/kg perflubron: Pperi = -1.6 +/- 0.7 mm Hg, CO = 3.4 +/- 0.2

94 Perflubron priming was achieved by instilling perflubron

95 Partial liquid ventilation with perflubron provides effective improvement in gas exchang

96 A minimal amount of perflubron remained in the lungs after 5.2 days.

97 Volatilized perflubron replacement was repeated daily for from 1 to

98 Perflubron symmetrically opacifies the lungs in a gravit

99 Within one hour after the instillation of perflubron, the arterial oxygen tension increased by 138

100 oup receiving high-frequency ventilation and perflubron, the combination of perflubron with high-freq

101 receive PLV (n = 65) with administration of perflubron through an endotracheal tube sideport or conv

102 Our data suggest that the optimal dose of perflubron to achieve the lowest oxygenation index durin

103 d ventilation animals received intratracheal perflubron to approximate functional residual capacity.

104 This study evaluates the ability of perflubron to inhibit pulmonary neutrophil accumulation

105 However, perflubron treatment did not affect RSV replication.

106 Liquid lung ventilation animals received perflubron via the endotracheal tube at either full func

107 erflubron priming was achieved by instilling perflubron via the endotracheal tube in an amount estima

108 Perflubron was administered into the trachea until the d

109 The distribution of perflubron was gravity dependent in four patients, with

110 rly radiographs were obtained until residual perflubron was minimal.

111 In one patient, perflubron was seen in a pneumatocele and the pleural sp

112 Extraparenchymal perflubron was seen in intrathoracic lymph nodes (n = 4)

113 A gravity-dependent distribution of perflubron was shown on 146 (95%) of 154 lateral radiogr

114 In the five survivors, minimal perflubron was visible up to 138 days.

115 xygenation with additional administration of perflubron were not greater than the improvements seen i

116 Lungs filled with perflubron were opacified to a similar degree in a gravi

117 nstrated in animals that received 3 mL/kg of perflubron with high-frequency oscillatory ventilation c

118 The combination of low-dose perflubron with high-frequency oscillatory ventilation l

119 ntilation and perflubron, the combination of perflubron with high-frequency oscillatory ventilation m